Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 11 - Drugs for disorders of the respiratory system
Patents for A61P 11 - Drugs for disorders of the respiratory system (87,767)
10/2002
10/17/2002WO2002081475A1 Jun kinase inhibitors
10/17/2002WO2002081463A1 Antagonists of mcp-1 function and methods of use thereof
10/17/2002WO2002081461A1 Piperazine derivatives as tachykinin antagonists
10/17/2002WO2002081449A1 Bipiperidinyl-derivatives and their use as chemokine receptors inhibitors
10/17/2002WO2002080979A2 Conjugate of hydroxyalkyl starch and an active agent
10/17/2002WO2002080926A1 Pyrazolopyrimidines as therapeutic agents
10/17/2002WO2002080908A1 Azolylcarbynol derivatives of aryl (or heteroaryl) for the treatment of respiratory diseases
10/17/2002WO2002080887A2 Timed pulse release composition
10/17/2002WO2002080884A2 Powder inhaler formulations
10/17/2002WO2002080859A2 Inhalation drug combinations
10/17/2002WO2002080754A2 Methods for using annexin for detecting cell death in vivo and treating associated conditions
10/17/2002WO2002080676A1 Erythropoietin ameliorates chemotherapy-induced toxicity in vivo
10/17/2002WO2002070524A3 N-but-3-enyl norbuprenorphine and its use as analgesic
10/17/2002WO2002059114A9 Lfa-1 antagonist compounds
10/17/2002WO2002057261A3 Diaminothiazoles and their use as inhibitors of cyclin-dependent kinase
10/17/2002WO2002047493A3 Health promoting compositions
10/17/2002WO2002043702A3 Pharmaceutical compositions for inhalation
10/17/2002WO2002043701A3 Method of making particles for use in a pharmaceutical composition
10/17/2002WO2002042292A3 Indol derivative and their use as inhibitors of p38 kinase
10/17/2002WO2002034726A3 Pyrimidine-2,4,6-trione metalloproteinase inhibitors
10/17/2002WO2002029061A3 G-protein coupled receptors
10/17/2002WO2001098323A3 G-protein coupled receptors
10/17/2002WO2001077378A3 Diagnosis of diseases associated with dna adducts
10/17/2002WO2001074404A3 Compositions containing genetically modified lung cancer cells expressing a tgf-beta inhibitor
10/17/2002WO2001041760A8 Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect
10/17/2002US20020151598 Bronchodilating compositions and methods
10/17/2002US20020151597 Formoterol, or a derivative; long term storage stability
10/17/2002US20020151588 Dissociated glucocorticoid receptor antagonists for the treatment of glucocorticoid associated side effects
10/17/2002US20020151572 Nitric oxide synthase (NOS); alone or in combination with another active agent for the treatment of psoriasis, an antiinflammatory, an analgesic, a cognition enhancer or sleep disorder treatment
10/17/2002US20020151558 Triazolo compounds as MMP inhibitors
10/17/2002US20020151554 Cyclin-dependent kinase inhibitors such as (4-Amino-2-((4-(4-methyl-1-piperazinyl)phenyl)amino)-5-thiazolyl) (2,3-dihydro-1,4-benzodioxin-6-yl)methanone for treatment of breast, lung, colon, and prostate cancer/tumors
10/17/2002US20020151553 Such as 4-(4-chlorophenyl)1-(3-(5-cyano-5H-dibenzo(a,d) cycloheptene-5-yl)propyl)piperidin-4-ol for treatment of diseases associated with aberrant leukocyte recruitment and/or activation
10/17/2002US20020151547 Substituted phenyl-piperidine methanone compounds
10/17/2002US20020151472 Trefoil factor (TFF) peptides (tricyclic peptides, e.g., TFF2 peptides), for increasing the viscosity of mucus layers; used for treating damaged or abnormal mucus layers, e.g. in the gastrointestinal tract, respiratory/urogential systems, eyes
10/17/2002US20020151009 Human polynucleotides, polypeptides, and antibodies
10/17/2002US20020150986 Extracellular matrix signalling molecules
10/17/2002US20020150980 Nucleotide sequences coding protein for use in the treatment of asthma, parkinson's, heart, hypotension, osteporosis and urogenital disorders
10/17/2002US20020150958 Detecting modulator of inflammation; obtain enzyme sample, incubate with modulator, monitor adjustment in enzyme activity, adjustment in activity indicate modulator
10/17/2002US20020150624 Mixture of drug, aminoacrylate polymer and acid
10/17/2002US20020150565 Treatment and prevention of reactive oxygen metabolite-mediated cellular damage
10/17/2002US20020150544 Water soluble film for oral administration with instant wettability
10/17/2002US20020148463 Use of intracellular calcium chelators to increase surfactant secretion in the lungs
10/17/2002DE10118550A1 New 3-ethanoylamino-3-phenyl-propionic acid derivatives, are integrin agonists or antagonists useful e.g. for treating angiogenic, cardiovascular, inflammatory, osteolytic or tumor diseases or infections
10/17/2002CA2699611A1 Desaturase genes and uses thereof
10/17/2002CA2698579A1 Desaturase genes and uses thereof
10/17/2002CA2443405A1 Use of cd25 binding molecules in steroid-resistant patients
10/17/2002CA2443277A1 Interferon gamma polypeptide variants
10/17/2002CA2443025A1 Erythropoietin ameliorates chemotherapy-induced toxicity in vivo
10/17/2002CA2443015A1 Aryl (or heteroaryl) azolylcarbinole derivatives for the treatment of respiratory diseases
10/17/2002CA2442776A1 Antagonists of mcp-1 function and methods of use thereof
10/17/2002CA2442739A1 Novel antibodies that bind to antigenic polypeptides, nucleic acids encoding the antigens, and methods of use
10/17/2002CA2442382A1 Methods for using annexin for detecting cell death in vivo and treating associated conditions
10/17/2002CA2441442A1 Conjugate of hydroxyalkyl starch and an active agent
10/17/2002CA2440724A1 Pyrazolopyrimidines as therapeutic agents
10/16/2002WO2001079186A1 2-guanidino-4-arylchinazolines as nhe-3 inhibitors
10/16/2002EP1249450A1 Benzimidazole derivatives
10/16/2002EP1249244A1 Therapeutic compositions for the treatment of a disease modulated by the G-actin / F-actin equilibrium, especially a respiratory tract disease
10/16/2002EP1248847A1 Irak-4: compositions and methods of use
10/16/2002EP1248842A1 2871 receptor, a g-protein coupled receptor and methods of use thereof
10/16/2002EP1248804A2 Recombinant antibodies to human interleukin-1 beta
10/16/2002EP1248787A2 Novel subtituted pyrazolo[4, 3-e]diazepines, pharmaceutical compositions containing them, use as medicinal products and processes for preparing them
10/16/2002EP1248785A1 Novel tetrahydropyridines, preparation method and pharmaceutical compositions containing same
10/16/2002EP1248781A1 Pyrazole cyclic amp-specific pde inhibitors
10/16/2002EP1248630A1 Composition, in particular cosmetic or dermatological composition, containing oligosaccharides and preparation method and cosmetic treatment method
10/16/2002EP1248629A1 Prevention and treatment of pulmonary bacterial infection or symptomatic pulmonary exposure to endotoxin by inhalation of antiendotoxin drugs
10/16/2002EP1248624A1 3,4-DIHYDRO-(1H)-QUINAZOLIN-2-ONES AND THEIR USE AS CSBP/p38 KINASE INHIBITORS
10/16/2002EP1248607A1 Urotensin-ii receptor antagonists
10/16/2002EP1248597A1 Pharmaceutical aerosol formulation of salmeterol and fluticasone propionate
10/16/2002EP1248595A1 Multi-step drug dosage forms
10/16/2002EP1248552A1 Pp14 fusion proteins and methods for making and using the same
10/16/2002EP1248517A2 Clonal propagation of primate offspring by embryo splitting
10/16/2002EP1210094A4 Herbal compositions and uses for the treatment of allergic reactions
10/16/2002EP1089737B1 Levosimendan for treating pulmonary hypertension
10/16/2002EP0991653B1 Novel compounds
10/16/2002EP0948509B1 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
10/16/2002EP0941108B1 Wound healing and treatment of fibrosis
10/16/2002EP0619742B1 Transfection of lung via aerosolized transgene delivery
10/16/2002CN1374967A Compounds for the treatment of ischemia
10/16/2002CN1374966A 嘌呤衍生物 Purine derivatives
10/16/2002CN1374962A 8-phenyl-6,9-dihydro-[1,2,4]triazolo[3,4-i] purin-5-one derivatives
10/16/2002CN1374961A Azepinoindole derivatives, the production and use thereof
10/16/2002CN1374952A Benzimidazolone derivatives and their use as phosphodiesterase inhibibors
10/16/2002CN1374872A Stabilization of macrolides
10/16/2002CN1374868A Pharmaceutical composition that contains eucalyptus and orange oil
10/16/2002CN1374865A Nociceptin receptor ORL-1 agonists for use in treating cough
10/16/2002CN1374858A For mulations for parenteral use of estramustine phosphate with improved pharmacological properties
10/16/2002CN1374857A Formulations for parenteral use of estramustine phosphate and sulfoalkyl ether cyclodextrins
10/16/2002CN1374130A Externally applied medicine fot treating nasosinusitis
10/16/2002CN1374120A Pseudozoogloea adjuvant and its prepn and application
10/16/2002CN1374119A Chinese medicine for treating acute and chronic rhinitis and nasosinusitis and its prepn process
10/16/2002CN1374113A New prepn process of Saorilao as one traditional Mongoliam medicine
10/16/2002CN1374111A New prepn process of Manu as one traditional Mongolian medicine
10/16/2002CN1374086A Neutrocyte functional inhibitor
10/16/2002CN1092659C Novel pyrimidine derivative
10/16/2002CN1092642C Quinoline derivatives as tachykinin NK 3 receptor antagonists
10/16/2002CN1092640C Imides as PDE III, PDE IV and TNF inhibitors
10/16/2002CN1092522C Traditional Chinese medicinal capsule for treating cough with dyspnea
10/16/2002CA2406161A1 2-guanidino-4-arylquinazolines as nhe-3 inhibitors
10/15/2002US6465686 Halogenated 2-amino-5,6 heptenoic acid derivatives useful as nitric oxide synthase inhibitors
10/15/2002US6465518 2-amino-5-fluoro-6-(1-iminoethylamino)-hept-4-enoic acid, for example; treating or preventing various causes of inflammation
1 ... 639 640 641 642 643 644 645 646 647 648 649 650 651 652 653 654 655 656 657 658 659 ... 878